Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer.

Lung Cancer (Auckl) · 2025 · PMC12004122 · PMID 40248685

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We further analyzed the different subsequent treatments with regard to the clinical outcomes, and found that the DCR and median PFS were better in the CT/IO (100% and 11.3 months) and CT/TKI (88.9% and 7.0 months) groups compared to the CT group (41.7% and 3.7 months), although the difference in PFS did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.